Alzheimer's disease is a progressive neurological disease of the brain that causes damage to neurons, leading to loss of memory and reasoning. It is the leading cause of dementia worldwide. The symptoms can affect a person’s ability to interact socially or function at work. Presently, there is no treatment that either halts or slows the progression of Alzheimer’s related dementia, delays its onset, or prevents it from occurring at all. Drugs are available to treat some of the symptoms, but these often only work temporarily. A treatment that can effectively halt or delay disease progression is urgently needed.
One possible way to achieve this is by preventing the aggregation of tau protein and the formation of tangles. Tau tangles are closely linked to the dementia seen in Alzheimer’s disease. They form inside brain cells when tau protein misfolds and begins to aggregate, ultimately causing brain cell death. TauRx has developed a drug compound that acts as a tau aggregation inhibitor. This drug has recently completed two phase 3 clinical trials for Alzheimer's disease.
Results from these trials has helped us to shape the current LUCIDITY phase 3 trial, which is underway at sites in the UK, North America, Canada, Spain, France, Italy and Poland. The previous trial results provided information about the optimal dose, which is much lower than previously anticipated, and data proving that our drug works best when given in isolation of other medication for Alzheimer’s disease. The LUCIDITY Study therefore uses low dose medication and is given as monotherapy.